Evaluation of mast cells in myeloproliferative disorders and myelodysplastic syndromes
- PMID: 15679425
- DOI: 10.5858/2005-129-219-EOMCIM
Evaluation of mast cells in myeloproliferative disorders and myelodysplastic syndromes
Abstract
Context: Mast cells may be increased as a reactive mastocytosis in various hematologic disorders and malignant neoplasms, as well as in systemic mast cell disease (SMCD). There are no statistical differences in mast cell numbers in reactive mastocytosis and SMCD; however, SMCD usually reveals dyspoietic mast cells and other dyspoietic bone marrow elements. In addition, SMCD is frequently (45%) associated with myeloproliferative disorders (MPDs) (17%) and myelodysplastic syndromes (MDSs) (28%). Thus, it has been suggested that SMCD may represent one aspect of a hematologic disorder that involves multiple bone marrow lineages.
Objective: To perform a systematic evaluation of MPDs and MDSs without SMCD for dyspoietic mast cells.
Design: A total of 55 MPDs or MDSs were reviewed, including 20 cytogenetically proven chronic myeloid leukemias, 6 essential thrombocythemias, 2 polycythemia veras, 21 cytogenetically proven MDSs, and 6 chronic myelomonocytic leukemias. Cases of idiopathic myelofibrosis were not included due to lack of spicules. The bone marrow aspirates were reviewed for an increase in mast cells (1+ to 3+), dyspoietic features within mast cells (decreased cytoplasmic granularity, uneven granule distribution), and a predominance of fusiform mast cells.
Results: All cases, except 2 MDSs, had evaluable bone marrow spicules. Of interest, the MPDs were significantly more associated with increased and dyspoietic mast cells (57% and 61%, respectively) than were the MDSs (11% and 4%, respectively). The 2 polycythemia veras and 6 chronic myelomonocytic leukemias did not reveal increased or dyspoietic mast cells.
Conclusions: These findings indicate that MPDs (chronic myeloid leukemia and essential thrombocythemia) frequently contain neoplastic mast cells as the spectrum of abnormal bone marrow cells. This feature, in conjunction with other parameters, may possibly be useful in the differential diagnosis of MPDs and MDSs. Our findings, compared with the previously reported findings in SMCD, suggest that SMCD may be more closely related to MPDs than to MDSs.
Similar articles
-
Bone marrow mast cell morphologic features and hematopoietic dyspoiesis in systemic mast cell disease.Am J Clin Pathol. 2001 Aug;116(2):177-82. doi: 10.1309/Q2WJ-46CL-YRFT-M5JF. Am J Clin Pathol. 2001. PMID: 11488063
-
Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera, and idiopathic myelofibrosis (agnogenic myeloid metaplasia).Int J Hematol. 2002 Aug;76(2):133-45. doi: 10.1007/BF02982575. Int J Hematol. 2002. PMID: 12215011 Review.
-
Hematologic manifestations of systemic mast cell disease: a prospective study of laboratory and morphologic features and their relation to prognosis.Am J Med. 1991 Dec;91(6):612-24. doi: 10.1016/0002-9343(91)90214-i. Am J Med. 1991. PMID: 1750431
-
Myelomastocytic overlap syndromes: biology, criteria, and relationship to mastocytosis.Leuk Res. 2001 Jul;25(7):595-602. doi: 10.1016/s0145-2126(01)00040-6. Leuk Res. 2001. PMID: 11377685 Review.
-
The role of beta-catenin in chronic myeloproliferative disorders.Hum Pathol. 2008 Oct;39(10):1454-8. doi: 10.1016/j.humpath.2008.02.007. Epub 2008 Jul 11. Hum Pathol. 2008. PMID: 18619646
Cited by
-
Study of significance of bone marrow microvessel density in myeloproliferative neoplasms in correlation with CD34 blasts, mast cell count and fibrosis.F1000Res. 2023 Oct 31;12:503. doi: 10.12688/f1000research.130522.2. eCollection 2023. F1000Res. 2023. PMID: 38434629 Free PMC article.
-
Advanced mast cell disease: an Italian Hematological Multicenter experience.Int J Hematol. 2008 Dec;88(5):483-488. doi: 10.1007/s12185-008-0166-4. Epub 2008 Nov 26. Int J Hematol. 2008. PMID: 19034614
-
High density of tryptase-positive mast cells in patients with multiple myeloma: correlation with parameters of disease activity.Tumour Biol. 2015 Nov;36(11):8491-7. doi: 10.1007/s13277-015-3586-9. Epub 2015 May 31. Tumour Biol. 2015. PMID: 26026586
MeSH terms
LinkOut - more resources
Full Text Sources
Medical